{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:24:31Z","timestamp":1777944271953,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited qualitative research on the patient experience of cutaneous lupus erythematosus (CLE), and no fit-for-purpose patient-reported outcome (PRO) instruments are currently available in this population. This study aimed to better characterise the disease experience of CLE, focusing on the most prevalent subtypes, discoid lupus erythematosus (DLE) and sub-acute CLE (SCLE), and to develop a conceptual model depicting the core signs, symptoms, and impacts of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Semi-structured, concept elicitation interviews were conducted in the United States among 25 patients with CLE (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 15 DLE;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10 SCLE) and three expert clinicians to explore the signs, symptoms, and impacts of CLE. Interviews were audio-recorded and verbatim transcripts were coded and thematically analysed. Concepts reported by \u2265 50% of patients with an average bothersome rating of \u22655\/10 were considered salient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most frequently reported signs and symptoms included itch (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 25\/25), skin lesions (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 24\/25), skin sensitivity to light (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 23\/25), skin redness (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 22\/25), skin scaling (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 20\/25), fatigue (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 21\/25), skin crusting, skin pain, joint pain, headaches (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 19\/25, each), and hair loss (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 18\/25). The most frequently reported impacts included limited social functioning (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 22\/25), body image concerns (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 21\/25), affected family\/partner relationships (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 19\/25), recreational\/leisure activities (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 18\/25), and sleep (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 16\/25). Key signs, symptoms, and impacts reported were generally consistent across SCLE and DLE subtypes, although patients with DLE reported greater scalp involvement and hair loss. The conceptual model summarises the core signs, symptoms, and impacts of CLE, while also highlighting any subtype-specific differences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides robust patient insights into the signs, symptoms, and impacts of CLE, with skin lesions, itch, skin sensitivity to light, hair loss, and fatigue emerging as most bothersome to patients. Scalp lesions warrant additional consideration due to their potential to cause permanent hair loss and scarring. This conceptual model can be used to identify target concepts for measurement and inform the development and selection of fit-for-purpose PRO instruments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033261435949","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:14:52Z","timestamp":1774602892000},"page":"688-698","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A conceptual model of the patient experience of cutaneous lupus erythematosus"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4753-8894","authenticated-orcid":false,"given":"Kate","family":"Burrows","sequence":"first","affiliation":[{"name":"Independent consultant for Sanofi, Gentilly, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Brookes","sequence":"additional","affiliation":[{"name":"Sanofi, Reading, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Lucats","sequence":"additional","affiliation":[{"name":"Sanofi, Gentilly, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane R","family":"Wells","sequence":"additional","affiliation":[{"name":"Sanofi, Reading, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeebah","family":"Adams","sequence":"additional","affiliation":[{"name":"Sanofi, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Steinerova","sequence":"additional","affiliation":[{"name":"IQVIA, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Saiwal","sequence":"additional","affiliation":[{"name":"IQVIA, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginchereau Sowell","family":"France","sequence":"additional","affiliation":[{"name":"IQVIA, New York, US"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0173-9"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10610.x"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10272.x"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318777103"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.21"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-023-01079-5"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000344"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.9026"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2000.00443.x"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.04.005"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12653"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2018.01.002"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.008"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000704"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.941003"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000529"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17911"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23889.x"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00117.x"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17012"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5048"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.017"},{"key":"e_1_3_9_24_2","volume-title":"FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making","year":"2024","unstructured":"FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. FDA, 2024."},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310370049"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17636"},{"key":"e_1_3_9_27_2","volume-title":"FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making","year":"2022","unstructured":"FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. FDA, 2022."},{"key":"e_1_3_9_28_2","volume-title":"Patient-Focused Drug Development: Methods to Identify What Is Important to Patients","year":"2022","unstructured":"Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. FDA, 2022."},{"key":"e_1_3_9_29_2","volume-title":"Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments","year":"2022","unstructured":"Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. FDA. 2022."},{"key":"e_1_3_9_30_2","volume-title":"Cutaneous lupus concerns from the patient perspective: a qualitative study","author":"Yan DA-O","year":"2020","unstructured":"Yan DA-O, Zamalin D, Chakka S, et al. Cutaneous lupus concerns from the patient perspective: a qualitative study. LID, 2020."},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2210711"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.11.014"},{"key":"e_1_3_9_33_2","first-page":"1524","volume-title":"Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument","author":"Patrick DL","year":"2011","unstructured":"Patrick DL, Burke L, Fau - Gwaltney CJ, et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. PRO, 2011, pp. 1524\u20134733."},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320958067"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000444"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261435949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033261435949","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261435949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:52:07Z","timestamp":1777708327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033261435949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/09612033261435949"],"URL":"https:\/\/doi.org\/10.1177\/09612033261435949","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}